Global Acinetobacter Infections Treatment Market Size, Manufacturers, Opportunities and Forecast to 2030

Global Acinetobacter Infections Treatment Market Size, Manufacturers, Opportunities and Forecast to 2030


Summary

Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or “species” of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.
Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.
Acinetobacter is often resistant to many commonly prescribed antibiotics. Decisions on treatment of infections with Acinetobacter should be made on a case-by-case basis by a healthcare provider. Acinetobacter infection typically occurs in ill patients and can either cause or contribute to death in these patients.

According to APO Research, The global Acinetobacter Infections Treatment market was estimated at US$ million in 2023 and is projected to reach a revised size of US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.

North American market for Acinetobacter Infections Treatment is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Acinetobacter Infections Treatment is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Acinetobacter Infections Treatment is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global companies of Acinetobacter Infections Treatment include Entasis Therapeutics, Roche, Adenium Biotech, Vaxdyn, Hsiri Therapeutics, Aridis Pharmaceuticals, LegoChem Biosciences, Atterx Biotherapeutics and Achaogen, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Acinetobacter Infections Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acinetobacter Infections Treatment.
The Acinetobacter Infections Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Acinetobacter Infections Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Entasis Therapeutics
Roche
Adenium Biotech
Vaxdyn
Hsiri Therapeutics
Aridis Pharmaceuticals
LegoChem Biosciences
Atterx Biotherapeutics
Achaogen
Peptilogics
Sealife PHARMA
Shionogi
Techulon
Tetraphase Pharmaceuticals
Acinetobacter Infections Treatment segment by Type

Sulbactam
Carbapenems
Aminoglycosides
Polymyxins
Tetracyclines
Others
Acinetobacter Infections Treatment segment by Pipeline
ETX2514
Nacubactam RG6080
Arenicin
VXD-001
Small Molecule Antibiotic
AR-401 mAB
LCB01-0371 (PO)
GN-4474
Antibacterial Antibody
Others
Acinetobacter Infections Treatment Segment by Region

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acinetobacter Infections Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Acinetobacter Infections Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acinetobacter Infections Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2019-2024, 2025-2030). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Acinetobacter Infections Treatment companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report


1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.3 Global Acinetobacter Infections Treatment Market Size Overview by Region 2019 VS 2023 VS 2030
1.4 Global Acinetobacter Infections Treatment Market Size by Region (2019-2030)
1.4.1 Global Acinetobacter Infections Treatment Market Size by Region (2019-2024)
1.4.2 Global Acinetobacter Infections Treatment Market Size by Region (2025-2030)
1.5 Key Regions Acinetobacter Infections Treatment Market Size (2019-2030)
1.5.1 North America Acinetobacter Infections Treatment Market Size Growth Rate (2019-2030)
1.5.2 Europe Acinetobacter Infections Treatment Market Size Growth Rate (2019-2030)
1.5.3 Asia-Pacific Acinetobacter Infections Treatment Market Size Growth Rate (2019-2030)
1.5.4 Latin America Acinetobacter Infections Treatment Market Size Growth Rate (2019-2030)
1.5.5 Middle East & Africa Acinetobacter Infections Treatment Market Size Growth Rate (2019-2030)
2 Acinetobacter Infections Treatment Market by Type
2.1 Type Introduction
2.1.1 Sulbactam
2.1.2 Carbapenems
2.1.3 Aminoglycosides
2.1.4 Polymyxins
2.1.5 Tetracyclines
2.1.6 Others
2.2 Global Acinetobacter Infections Treatment Market Size by Type
2.2.1 Global Acinetobacter Infections Treatment Market Size Overview by Type (2019-2030)
2.2.2 Global Acinetobacter Infections Treatment Historic Market Size Review by Type (2019-2024)
2.2.3 Global Acinetobacter Infections Treatment Market Size Forecasted by Type (2025-2030)
2.3 Global Acinetobacter Infections Treatment Market Size by Regions
2.3.1 North America Acinetobacter Infections Treatment Market Size Breakdown by Type (2019-2024)
2.3.2 Europe Acinetobacter Infections Treatment Market Size Breakdown by Type (2019-2024)
2.3.3 Asia-Pacific Acinetobacter Infections Treatment Market Size Breakdown by Type (2019-2024)
2.3.4 Latin America Acinetobacter Infections Treatment Market Size Breakdown by Type (2019-2024)
2.3.5 Middle East and Africa Acinetobacter Infections Treatment Market Size Breakdown by Type (2019-2024)
3 Acinetobacter Infections Treatment Market by Pipeline
3.1 Type Introduction
3.1.1 ETX2514
3.1.2 Nacubactam RG6080
3.1.3 Arenicin
3.1.4 VXD-001
3.1.5 Small Molecule Antibiotic
3.1.6 AR-401 mAB
3.1.7 LCB01-0371 (PO)
3.1.8 GN-4474
3.1.9 Antibacterial Antibody
3.1.10 Others
3.2 Global Acinetobacter Infections Treatment Market Size by Pipeline
3.2.1 Global Acinetobacter Infections Treatment Market Size Overview by Pipeline (2019-2030)
3.2.2 Global Acinetobacter Infections Treatment Historic Market Size Review by Pipeline (2019-2024)
3.2.3 Global Acinetobacter Infections Treatment Market Size Forecasted by Pipeline (2025-2030)
3.3 Global Acinetobacter Infections Treatment Market Size by Regions
3.3.1 North America Acinetobacter Infections Treatment Market Size Breakdown by Pipeline (2019-2024)
3.3.2 Europe Acinetobacter Infections Treatment Market Size Breakdown by Pipeline (2019-2024)
3.3.3 Asia-Pacific Acinetobacter Infections Treatment Market Size Breakdown by Pipeline (2019-2024)
3.3.4 Latin America Acinetobacter Infections Treatment Market Size Breakdown by Pipeline (2019-2024)
3.3.5 Middle East and Africa Acinetobacter Infections Treatment Market Size Breakdown by Pipeline (2019-2024)
4 Global Market Dynamics
4.1 Acinetobacter Infections Treatment Industry Trends
4.2 Acinetobacter Infections Treatment Industry Drivers
4.3 Acinetobacter Infections Treatment Industry Opportunities and Challenges
4.4 Acinetobacter Infections Treatment Industry Restraints
5 Competitive Insights by Company
5.1 Global Top Players by Acinetobacter Infections Treatment Revenue (2019-2024)
5.2 Global Acinetobacter Infections Treatment Industry Company Ranking, 2022 VS 2023 VS 2024
5.3 Global Acinetobacter Infections Treatment Key Company Headquarters & Area Served
5.4 Global Acinetobacter Infections Treatment Company, Product Type & Application
5.5 Global Acinetobacter Infections Treatment Company Commercialization Time
5.6 Market Competitive Analysis
5.6.1 Global Acinetobacter Infections Treatment Market CR5 and HHI
5.6.2 Global Top 5 and 10 Acinetobacter Infections Treatment Players Market Share by Revenue in 2023
5.6.3 2023 Acinetobacter Infections Treatment Tier 1, Tier 2, and Tier 3
6 Company Profiles
6.1 Entasis Therapeutics
6.1.1 Entasis Therapeutics Comapny Information
6.1.2 Entasis Therapeutics Business Overview
6.1.3 Entasis Therapeutics Acinetobacter Infections Treatment Revenue, Global Share and Gross Margin (2019-2024)
6.1.4 Entasis Therapeutics Acinetobacter Infections Treatment Product Portfolio
6.1.5 Entasis Therapeutics Recent Developments
6.2 Roche
6.2.1 Roche Comapny Information
6.2.2 Roche Business Overview
6.2.3 Roche Acinetobacter Infections Treatment Revenue, Global Share and Gross Margin (2019-2024)
6.2.4 Roche Acinetobacter Infections Treatment Product Portfolio
6.2.5 Roche Recent Developments
6.3 Adenium Biotech
6.3.1 Adenium Biotech Comapny Information
6.3.2 Adenium Biotech Business Overview
6.3.3 Adenium Biotech Acinetobacter Infections Treatment Revenue, Global Share and Gross Margin (2019-2024)
6.3.4 Adenium Biotech Acinetobacter Infections Treatment Product Portfolio
6.3.5 Adenium Biotech Recent Developments
6.4 Vaxdyn
6.4.1 Vaxdyn Comapny Information
6.4.2 Vaxdyn Business Overview
6.4.3 Vaxdyn Acinetobacter Infections Treatment Revenue, Global Share and Gross Margin (2019-2024)
6.4.4 Vaxdyn Acinetobacter Infections Treatment Product Portfolio
6.4.5 Vaxdyn Recent Developments
6.5 Hsiri Therapeutics
6.5.1 Hsiri Therapeutics Comapny Information
6.5.2 Hsiri Therapeutics Business Overview
6.5.3 Hsiri Therapeutics Acinetobacter Infections Treatment Revenue, Global Share and Gross Margin (2019-2024)
6.5.4 Hsiri Therapeutics Acinetobacter Infections Treatment Product Portfolio
6.5.5 Hsiri Therapeutics Recent Developments
6.6 Aridis Pharmaceuticals
6.6.1 Aridis Pharmaceuticals Comapny Information
6.6.2 Aridis Pharmaceuticals Business Overview
6.6.3 Aridis Pharmaceuticals Acinetobacter Infections Treatment Revenue, Global Share and Gross Margin (2019-2024)
6.6.4 Aridis Pharmaceuticals Acinetobacter Infections Treatment Product Portfolio
6.6.5 Aridis Pharmaceuticals Recent Developments
6.7 LegoChem Biosciences
6.7.1 LegoChem Biosciences Comapny Information
6.7.2 LegoChem Biosciences Business Overview
6.7.3 LegoChem Biosciences Acinetobacter Infections Treatment Revenue, Global Share and Gross Margin (2019-2024)
6.7.4 LegoChem Biosciences Acinetobacter Infections Treatment Product Portfolio
6.7.5 LegoChem Biosciences Recent Developments
6.8 Atterx Biotherapeutics
6.8.1 Atterx Biotherapeutics Comapny Information
6.8.2 Atterx Biotherapeutics Business Overview
6.8.3 Atterx Biotherapeutics Acinetobacter Infections Treatment Revenue, Global Share and Gross Margin (2019-2024)
6.8.4 Atterx Biotherapeutics Acinetobacter Infections Treatment Product Portfolio
6.8.5 Atterx Biotherapeutics Recent Developments
6.9 Achaogen
6.9.1 Achaogen Comapny Information
6.9.2 Achaogen Business Overview
6.9.3 Achaogen Acinetobacter Infections Treatment Revenue, Global Share and Gross Margin (2019-2024)
6.9.4 Achaogen Acinetobacter Infections Treatment Product Portfolio
6.9.5 Achaogen Recent Developments
6.10 Peptilogics
6.10.1 Peptilogics Comapny Information
6.10.2 Peptilogics Business Overview
6.10.3 Peptilogics Acinetobacter Infections Treatment Revenue, Global Share and Gross Margin (2019-2024)
6.10.4 Peptilogics Acinetobacter Infections Treatment Product Portfolio
6.10.5 Peptilogics Recent Developments
6.11 Sealife PHARMA
6.11.1 Sealife PHARMA Comapny Information
6.11.2 Sealife PHARMA Business Overview
6.11.3 Sealife PHARMA Acinetobacter Infections Treatment Revenue, Global Share and Gross Margin (2019-2024)
6.11.4 Sealife PHARMA Acinetobacter Infections Treatment Product Portfolio
6.11.5 Sealife PHARMA Recent Developments
6.12 Shionogi
6.12.1 Shionogi Comapny Information
6.12.2 Shionogi Business Overview
6.12.3 Shionogi Acinetobacter Infections Treatment Revenue, Global Share and Gross Margin (2019-2024)
6.12.4 Shionogi Acinetobacter Infections Treatment Product Portfolio
6.12.5 Shionogi Recent Developments
6.13 Techulon
6.13.1 Techulon Comapny Information
6.13.2 Techulon Business Overview
6.13.3 Techulon Acinetobacter Infections Treatment Revenue, Global Share and Gross Margin (2019-2024)
6.13.4 Techulon Acinetobacter Infections Treatment Product Portfolio
6.13.5 Techulon Recent Developments
6.14 Tetraphase Pharmaceuticals
6.14.1 Tetraphase Pharmaceuticals Comapny Information
6.14.2 Tetraphase Pharmaceuticals Business Overview
6.14.3 Tetraphase Pharmaceuticals Acinetobacter Infections Treatment Revenue, Global Share and Gross Margin (2019-2024)
6.14.4 Tetraphase Pharmaceuticals Acinetobacter Infections Treatment Product Portfolio
6.14.5 Tetraphase Pharmaceuticals Recent Developments
7 North America
7.1 North America Acinetobacter Infections Treatment Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
7.2 North America Acinetobacter Infections Treatment Market Size by Country (2019-2024)
7.3 North America Acinetobacter Infections Treatment Market Size Forecast by Country (2025-2030)
8 Europe
8.1 Europe Acinetobacter Infections Treatment Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
8.2 Europe Acinetobacter Infections Treatment Market Size by Country (2019-2024)
8.3 Europe Acinetobacter Infections Treatment Market Size Forecast by Country (2025-2030)
9 Asia-Pacific
9.1 Asia-Pacific Acinetobacter Infections Treatment Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
9.2 Asia-Pacific Acinetobacter Infections Treatment Market Size by Country (2019-2024)
9.3 Asia-Pacific Acinetobacter Infections Treatment Market Size Forecast by Country (2025-2030)
10 Latin America
10.1 Latin America Acinetobacter Infections Treatment Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
10.2 Latin America Acinetobacter Infections Treatment Market Size by Country (2019-2024)
10.3 Latin America Acinetobacter Infections Treatment Market Size Forecast by Country (2025-2030)
11 Middle East & Africa
11.1 Middle East & Africa Acinetobacter Infections Treatment Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
11.2 Middle East & Africa Acinetobacter Infections Treatment Market Size by Country (2019-2024)
11.3 Middle East & Africa Acinetobacter Infections Treatment Market Size Forecast by Country (2025-2030)
12 Concluding Insights
13 Appendix
13.1 Reasons for Doing This Study
13.2 Research Methodology
13.3 Research Process
13.4 Authors List of This Report
13.5 Data Source
13.5.1 Secondary Sources
13.5.2 Primary Sources

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings